Champions Oncology, Inc. Stock News

HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing (CTL), part of Enterprise Innovation at Weill Cornell Medicine. This strategic collaboration will allow Champions Oncol...

Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2025 Earnings Conference Call September 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group Operator Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2025 Earnings Call.

HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024. First Quarter Highlights: Total revenue increased 12% to $14.1 million Margin improved to 50% Adjusted E...

HACKENSACK, NJ / ACCESSWIRE / September 9, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the first quarter ended July 31, 2024, on Wednesday, September 11, 2024, after market close. The company will host a conference call to discuss the results ...

Champions Oncology, Inc. (NASDAQ:CSBR ) Q4 2024 Earnings Conference Call July 18, 2024 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Matthew Hewitt - Craig-Hallum Operator Greetings. Welcome to Champions Oncology's Fourth Quarter Fiscal Year 2024 Earnings Conference Call.

Annual Revenue of $50.2 Million HACKENSACK, NJ / ACCESSWIRE / July 18, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2024. Fourth Quarter Financial Highlights: Fourth quarter revenue increased 7% to $14 million Adjusted EBITDA four...

HACKENSACK, NJ / ACCESSWIRE / July 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the fourth quarter and year-ended April 30, 2024, on Thursday, July 18, 2024, after market close. The company will host a conference call to discuss the ...

HACKENSACK, NJ / ACCESSWIRE / June 4, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, has announced a strategic partnership with Medicines Discovery Catapult (MDC), enhancing their combined capabilities in the expanding field of radiopharmaceutical therapeutics. This collaboration combines Champions Oncology's robust portfol...